Bone Abstracts

Over the past two years we have continued to see new developments and findings in paediatric bone disease that will help change and modify our clinical practice. I have selected some pertinent publications and divided these into different themes that I intend to highlight in this presentation. These include:

(1) New treatment options – Burosumab for X-linked Hypophosphataemic Rickets and Anti-Sclerostin antibody for Osteogenesis Imperfecta.

(2) New conditions and management – a novel form of Vitamin D dependant rickets and a consensus statement on Pseudohypoparathyroidism.

(3)Longitudinal follow up studies – femoral fractures in Osteogenesis Imperfecta, scoliosis in Fibrous Dysplasia, vertebral fractures in Leukaemia and following discontinuation of Denosumab.

(4) Vitamin D – new evidence of potential benefits or lack of benefit in infections, fracture risk and bone density.

Disclosure: The author declared no competing interests.

Abstract unavailable.